The stock of Gain Therapeutics Inc (GANX) has gone down by -9.76% for the week, with a -20.71% drop in the past month and a -43.58% drop in the past quarter. The volatility ratio for the week is 8.90%, and the volatility levels for the past 30 days are 8.40% for GANX.. The simple moving average for the past 20 days is -13.55% for GANX’s stock, with a -22.48% simple moving average for the past 200 days.
Is It Worth Investing in Gain Therapeutics Inc (NASDAQ: GANX) Right Now?
GANX has 36-month beta value of 0.53. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for GANX is 15.09M, and currently, short sellers hold a 0.99% ratio of that float. The average trading volume of GANX on May 09, 2024 was 134.79K shares.
GANX) stock’s latest price update
The stock of Gain Therapeutics Inc (NASDAQ: GANX) has decreased by -7.59 when compared to last closing price of 2.90.Despite this, the company has seen a loss of -9.76% in its stock price over the last five trading days. Zacks Investment Research reported 2024-05-03 that Gain Therapeutics (GANX) doesn’t possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts’ Opinion of GANX
Many brokerage firms have already submitted their reports for GANX stocks, with Oppenheimer repeating the rating for GANX by listing it as a “Outperform.” The predicted price for GANX in the upcoming period, according to Oppenheimer is $30 based on the research report published on April 12, 2021 of the previous year 2021.
BTIG Research, on the other hand, stated in their research note that they expect to see GANX reach a price target of $30. The rating they have provided for GANX stocks is “Buy” according to the report published on April 12th, 2021.
GANX Trading at -28.70% from the 50-Day Moving Average
After a stumble in the market that brought GANX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -52.23% of loss for the given period.
Volatility was left at 8.40%, however, over the last 30 days, the volatility rate increased by 8.90%, as shares sank -19.76% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -42.12% lower at present.
During the last 5 trading sessions, GANX fell by -9.76%, which changed the moving average for the period of 200-days by -35.42% in comparison to the 20-day moving average, which settled at $3.07. In addition, Gain Therapeutics Inc saw -17.92% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GANX starting from Riley Jeffrey Scott, who purchase 30,000 shares at the price of $3.86 back on Mar 28 ’24. After this action, Riley Jeffrey Scott now owns 30,000 shares of Gain Therapeutics Inc, valued at $115,770 using the latest closing price.
Alder Matthias, the Chief Executive Officer of Gain Therapeutics Inc, sale 206 shares at $2.46 during a trade that took place back on Dec 21 ’23, which means that Alder Matthias is holding 5,286 shares at $507 based on the most recent closing price.
Stock Fundamentals for GANX
Current profitability levels for the company are sitting at:
- -403.28 for the present operating margin
- -0.51 for the gross margin
The net margin for Gain Therapeutics Inc stands at -403.54. The total capital return value is set at -1.63. Equity return is now at value -141.57, with -104.28 for asset returns.
Based on Gain Therapeutics Inc (GANX), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -23.65. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is -146.37.
Currently, EBITDA for the company is -22.17 million with net debt to EBITDA at 0.49. When we switch over and look at the enterprise to sales, we see a ratio of 681.62. The receivables turnover for the company is 0.23for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.59.
Conclusion
To put it simply, Gain Therapeutics Inc (GANX) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
